Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminoserine SCHEMBL277837 | 0.89 | — | — | |
| Aminoserine SCHEMBL277836 | 0.89 | — | — | |
| Aminoserine SCHEMBL8333262 | 0.89 | — | — | |
| Aminoserine SCHEMBL853081 | 0.86 | — | — | |
| Aminoserine SCHEMBL5114875 | 0.86 | — | — | |
| Aminoserine SCHEMBL853082 | 0.86 | — | — | |
| Aminoserine SCHEMBL15668067 | 0.83 | SLC1A1 (0.37) | SLC1A1ALOX15BLMPMP22KMT2A | |
| Aminoserine SCHEMBL8506214 | 0.83 | — | — | |
| Aminoserine SCHEMBL8506211 | 0.83 | — | — | |
| Aminoserine SCHEMBL17491742 | 0.79 | LMNA (0.47) | SLC1A1ALOX15BLMPMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645792-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7241807-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | CYP2C19, CYP3A5, CYP3A4 | SLC1A1 154/4885AKR1B1 3247/4885ALOX15 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.